Fukumoto Chonji, Ogisawa Shouhei, Tani Masashi, Hyodo Toshiki, Kamimura Ryouta, Sawatani Yuta, Hasegawa Tomonori, Komiyama Yuske, Fujita Atsushi, Wakui Takahiro, Haruyama Yasuo, Kobashi Gen, Kawamata Hitoshi
Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.
Section of Dentistry, Oral and Maxillofacial Surgery, Sano Kosei General Hospital, 1728 Horigome town, Sano city, Tochigi, 327-8511, Japan.
BMC Geriatr. 2020 Nov 20;20(1):487. doi: 10.1186/s12877-020-01902-3.
The status of oral cancer therapy in elderly patients in Japan, where ageing is rapidly progressing, may serve as a model for other countries with similar demographics. There is controversy over what kind of treatment should be applied and how aggressively it should be applied to very elderly patients who have exceeded the average life expectancy. Given that 85 years is approximately the overall Japanese life expectancy at birth, we considered a threshold of 85 years and hypothesized that the prognosis of oral squamous cell carcinoma (SCC) patients aged ≥85 years was not inferior to that of those < 85 years. The aim of the present study was to investigate the clinical characteristics, treatment methods, and prognoses of Japanese oral SCC patients aged ≥85 years.
A retrospective cohort study was performed. The data of patients with primary oral SCC (n = 358) from 2005 to 2018 in our institute were extracted from electronic medical records. A total of 358 patients with oral SCC were divided into two groups (≥85 years group [n = 26] and < 85 years group [n = 332]) based on the age threshold of 85 years at the first visit. Kaplan-Meier survival analyses and Cox proportional hazard models were used to analyse overall survival (OS) and hazard ratios (HRs) according to age group, treatment, and TNM classification.
There was no difference in the 5-year OS rate between the ≥85 years and < 85 years groups (80.8% vs. 82.2%, P = 0.359). This finding was the same in the operative (94.7% vs. 85.8%, P = 0.556) and non-operative (42.9% vs. 33.2%, P = 0.762) groups, indicating that age did not affect prognosis. Mortality was lower in the operative group than in the non-operative group (adjusted HR: 0.276, 95% CI: 0.156-0.489, P < 0.001), suggesting that surgery is a superior method. However, non-surgical treatment was selected at a higher rate in the ≥85 years group (26.9% vs. 11.1%, P = 0.028).
This study suggests the prognosis of ≥85-year-old patients was not inferior to that of < 85-year-old patients. We recommend that surgery as the first choice treatment for ≥85-year-old patients with oral SCC who can tolerate surgery should be performed.
在老龄化迅速发展的日本,老年口腔癌患者的治疗现状可作为其他人口结构相似国家的范例。对于那些超过平均预期寿命的高龄患者,应采用何种治疗方法以及治疗的积极程度如何,存在争议。鉴于85岁左右是日本人的总体出生预期寿命,我们设定了85岁的阈值,并假设年龄≥85岁的口腔鳞状细胞癌(SCC)患者的预后并不逊于年龄<85岁的患者。本研究的目的是调查年龄≥85岁的日本口腔SCC患者的临床特征、治疗方法和预后。
进行了一项回顾性队列研究。从我院2005年至2018年的电子病历中提取原发性口腔SCC患者(n = 358)的数据。根据首次就诊时85岁的年龄阈值,将358例口腔SCC患者分为两组(≥85岁组[n = 26]和<85岁组[n = 332])。采用Kaplan-Meier生存分析和Cox比例风险模型,根据年龄组、治疗方法和TNM分类分析总生存期(OS)和风险比(HRs)。
≥85岁组和<85岁组的5年OS率无差异(80.8%对82.2%,P = 0.359)。在手术组(94.7%对85.8%,P = 0.556)和非手术组(42.9%对33.2%,P = 0.762)中也是如此,这表明年龄不影响预后。手术组的死亡率低于非手术组(调整后的HR:0.276,95%CI:0.156 - 0.489,P<0.001),这表明手术是一种更好的方法。然而,≥85岁组选择非手术治疗的比例更高(26.9%对11.1%,P = 0.028)。
本研究表明,年龄≥85岁患者的预后并不逊于年龄<85岁的患者。我们建议,对于能够耐受手术的年龄≥85岁的口腔SCC患者,应首选手术治疗。